Medical Oncologist, focused on Neuro-Oncology and Early Drug Development | Master in Business © - Health Industry (Universidad de San Andrés)
📑 EANO European Association of Neuro-Oncology Guideline on molecular testing for Meningiomas for targeted therapy selection. 🧬 Meningiomas can express a wide range of molecular alterations and markers including NF2, AKT1, SMO, SMARCE1, PIK3CA, CDKN2A/B, CDK4/6, TERT, TRAF7, BAP1, KLF4, ARID1/2, SUFU, PD-L1, SSTR2A, PR/ER, mTOR, VEGFR, PDGFR, as well as homologous recombination deficiency (HRD), genomic copy number variations, DNA methylation classes and combined gene expression profiles. 🎯 Based on the established ESMO ESCAT (European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets) evidence level criteria, unfortunately, no molecular target reached ESCAT I (“ready for clinical use”) classification and only mTOR pathway activation and NF2 alterations reached ESCAT II (“investigational”) classification, respectively. 💡 This highlights the need for future research and innovative trial design that incorporates molecular profiling that allows for the evaluation of targeted therapy in these tumors. #neuronc #medonc #meningiomas #eano #targeted #therapy #molecular #profiling #personalized #medicine
Just Released: The EANO Guideline on molecular testing of meningiomas for targeted therapy selection! Evidence-based guidance for patient care & clinical trials, and show of areas for which additional research is warranted. Learn more: https://lnkd.in/e7NgkWM2 #EANO #EANOguideline #Meningioma #TargetedTherapy #ICOM
